Lumigan - General Information:

Lumigan ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It binds to the prostanoid FP receptor.


Lumigan is a prostamide, a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Lumigan lowers intraocular pressure (IOP) in humans. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

Lumigan for patients

Patients should be informed that LUMIGAN™ has been reported to cause increased growth and darkening of eyelashes and darkening of the skin around the eye in some patients. These changes may be permanent.

Some patients may slowly develop darkening of the iris, which may be permanent.

When only one eye is treated, patients should be informed of the potential for a cosmetic difference between the eyes in eyelash length, darkness or thickness, and/or color changes of the eyelid skin or iris.

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Patients should also be advised that if they develop an intercurrent ocular condition (e.g., trauma or infection) or have ocular surgery, they should immediately seek their physician's advice concerning the continued use of the multidose container.

Patients should be advised that if they develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician's advice.

Contact lenses should be removed prior to instillation of LUMIGAN™ and may be reinserted 15 minutes following its administration. Patients should be advised that LUMIGAN™ contains benzalkonium chloride, which may be absorbed by soft contact lenses.

If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications.

Lumigan Interactions

No Information Provided

Lumigan Contraindications

LUMIGAN™ (bimatoprost ophthalmic solution) 0.03% is contraindicated in patients with hypersensitivity to bimatoprost or any other ingredient in this product.

Additional information about Lumigan

Lumigan Indication: For the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Mechanism Of Action: Lumigan is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Lumigan reduces the pressure in the eye by mimicking the action of a naturally-occuring prostaglandin. Prostaglandins are a group of chemicals found in many places in the body. In the eye, they increase the drainage of the aqueous humour out of the eyeball. Lumigan is a synthetic compound related to one of the natural prostaglandins, and works by increasing the drainage of aqueous humour out of the eyeball. This decreases the pressure within the eye.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Bimatoprost
Synonyms: AGN 192024
Drug Category: Antiglaucomic Agents; Antihypertensive Agents
Drug Type: Small Molecule; Approved
Other Brand Names containing Bimatoprost: Lumigan;
Absorption: Systemically absorbed when administered to the eye.
Toxicity (Overdose): In oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m2 is at least 70 times higher than the accidental dose of one bottle of bimatoprost for a 10 kg child.
Protein Binding: Approximately 88% of bimatoprost is bound in human plasma.
Biotransformation: Bimatoprost undergoes oxidation, N-deethylation and glucuronidation to form a variety of metabolites.
Half Life: Elimination half-life is approximately 45 minutes.
Dosage Forms of Lumigan: Solution Ophthalmic
Chemical IUPAC Name: (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
Chemical Formula: C25H37NO4
Bimatoprost on Wikipedia:
Organisms Affected: Humans and other mammals

Bookmark or Share this page

»Get link codes for this page«
(HTML/BB code)

Search by name browsing our [A-Z] index:


Search by Categories:

See a list of all drugs for sale »

Top5 meds in current month:

*based on number of page views on Flexyx

Visit our friends:

brand and generic ed pills Russian Scientific Center for Restorative Traumatology and Orthopaedics in the name of academician G.A.Ilizarov

Related News

Fri, 18 May 2012
Bimatoprost (Lumigan) - Drug Dosage and Side Effects - Healthline
What is this medicine. How should I use this medicine. What should I tell my health care provider before I take this medicine. What may interact with this medicine. What if I miss a dose.
Source: »

Tue, 03 Apr 2012
Watson Confirms LUMIGAN(R) and LATISSE(R) Patent Challenges - Seeking Alpha
Tue April 3, 2012 9:15 AM about. April 3, 2012 /PRNewswire.
Source: »

Tue, 03 Apr 2012
Watson seeks approval for generic Lumigan, Latisse - Drug Store News
Allergan, Duke University sue to prevent launch. Watson is challenging the patent protection on two eye drugs made by Allergan, the generic drug maker said Tuesday.
Source: »

Thanks for visiting us!